世界の非アルコール性脂肪性肝炎(NASH)治療薬市場インサイト及び予測(~2026年)

【英語タイトル】Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026

QYResearchが出版した調査資料(QYR20NV03995)・商品コード:QYR20NV03995
・発行会社(調査会社):QYResearch
・発行日:2020年11月(※2024年版があります。お問い合わせください)
・ページ数:95
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは非アルコール性脂肪性肝炎(NASH)治療薬の世界市場について調査・分析した資料です。種類別(ビタミンE&ピオグリタゾン、オベチコール酸(OCA)、エラフィブラノール、セロンセルチブ&セニクリビロク)の市場規模、用途別(病院薬局、オンラインプロバイダー、小売薬局)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別非アルコール性脂肪性肝炎(NASH)治療薬の競争状況、市場シェア
・世界の非アルコール性脂肪性肝炎(NASH)治療薬市場:種類別市場規模 2015年-2020年(ビタミンE&ピオグリタゾン、オベチコール酸(OCA)、エラフィブラノール、セロンセルチブ&セニクリビロク)
・世界の非アルコール性脂肪性肝炎(NASH)治療薬市場:種類別市場規模予測 2021年-2026年(ビタミンE&ピオグリタゾン、オベチコール酸(OCA)、エラフィブラノール、セロンセルチブ&セニクリビロク)
・世界の非アルコール性脂肪性肝炎(NASH)治療薬市場:用途別市場規模 2015年-2020年(病院薬局、オンラインプロバイダー、小売薬局)
・世界の非アルコール性脂肪性肝炎(NASH)治療薬市場:用途別市場規模予測 2021年-2026年(病院薬局、オンラインプロバイダー、小売薬局)
・北米の非アルコール性脂肪性肝炎(NASH)治療薬市場分析:米国、カナダ
・ヨーロッパの非アルコール性脂肪性肝炎(NASH)治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの非アルコール性脂肪性肝炎(NASH)治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の非アルコール性脂肪性肝炎(NASH)治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの非アルコール性脂肪性肝炎(NASH)治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):AstraZeneca、Conatus Pharmaceuticals、Enzo Biochem、Galmed Pharmaceuticals、Genfit、Gilead、Horizon Pharma、Immuron、Intercept Pharmaceuticals、Novo Nordisk
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.

Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk

Market segment by Type, the product can be split into
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market segment by Application, split into
Hospital Pharmacy
Online Provider
Retail Pharmacy

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
1.4 Market by Type
1.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Vitamin E & Pioglitazone
1.4.3 Obeticholic Acid (OCA)
1.4.4 Elafibranor
1.4.5 Selonsertib & Cenicriviroc
1.5 Market by Application
1.5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacy
1.5.3 Online Provider
1.5.4 Retail Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026)
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Alcoholic Steatohepatitis (NASH) Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
3.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players Head office and Area Served
3.4 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
3.5 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
6.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in North America (2019-2020)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
7.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Europe (2019-2020)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

8 China
8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
8.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in China (2019-2020)
8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
9.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Japan (2019-2020)
9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
10.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

11 India
11.1 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
11.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in India (2019-2020)
11.3 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
11.4 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2020)
12.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Conatus Pharmaceuticals
13.2.1 Conatus Pharmaceuticals Company Details
13.2.2 Conatus Pharmaceuticals Business Overview
13.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.2.5 Conatus Pharmaceuticals Recent Development
13.3 Enzo Biochem
13.3.1 Enzo Biochem Company Details
13.3.2 Enzo Biochem Business Overview
13.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.3.5 Enzo Biochem Recent Development
13.4 Galmed Pharmaceuticals
13.4.1 Galmed Pharmaceuticals Company Details
13.4.2 Galmed Pharmaceuticals Business Overview
13.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.4.5 Galmed Pharmaceuticals Recent Development
13.5 Genfit
13.5.1 Genfit Company Details
13.5.2 Genfit Business Overview
13.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.5.5 Genfit Recent Development
13.6 Gilead
13.6.1 Gilead Company Details
13.6.2 Gilead Business Overview
13.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.6.5 Gilead Recent Development
13.7 Horizon Pharma
13.7.1 Horizon Pharma Company Details
13.7.2 Horizon Pharma Business Overview
13.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.7.5 Horizon Pharma Recent Development
13.8 Immuron
13.8.1 Immuron Company Details
13.8.2 Immuron Business Overview
13.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.8.5 Immuron Recent Development
13.9 Intercept Pharmaceuticals
13.9.1 Intercept Pharmaceuticals Company Details
13.9.2 Intercept Pharmaceuticals Business Overview
13.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.9.5 Intercept Pharmaceuticals Recent Development
13.10 Novo Nordisk
13.10.1 Novo Nordisk Company Details
13.10.2 Novo Nordisk Business Overview
13.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
13.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
13.10.5 Novo Nordisk Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
Table 3. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Vitamin E & Pioglitazone
Table 6. Key Players of Obeticholic Acid (OCA)
Table 7. Key Players of Elafibranor
Table 8. Key Players of Selonsertib & Cenicriviroc
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2015-2020)
Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Strategy
Table 19. Main Points Interviewed from Key Non-Alcoholic Steatohepatitis (NASH) Drugs Players
Table 20. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2015-2020) (Million US$)
Table 21. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2015-2020)
Table 22. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019)
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
Table 26. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2015-2020)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2021-2026)
Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2015-2020)
Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 33. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2021-2026)
Table 34. North America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 38. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 39. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 40. Europe Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 46. China Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 47. China Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 48. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 49. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 50. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 51. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 52. Japan Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 54. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 56. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 60. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 62. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 64. India Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 65. India Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 66. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 67. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 68. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 69. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share (2019-2020)
Table 72. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020)
Table 74. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020)
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Product
Table 79. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 80. AstraZeneca Recent Development
Table 81. Conatus Pharmaceuticals Company Details
Table 82. Conatus Pharmaceuticals Business Overview
Table 83. Conatus Pharmaceuticals Product
Table 84. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 85. Conatus Pharmaceuticals Recent Development
Table 86. Enzo Biochem Company Details
Table 87. Enzo Biochem Business Overview
Table 88. Enzo Biochem Product
Table 89. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 90. Enzo Biochem Recent Development
Table 91. Galmed Pharmaceuticals Company Details
Table 92. Galmed Pharmaceuticals Business Overview
Table 93. Galmed Pharmaceuticals Product
Table 94. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 95. Galmed Pharmaceuticals Recent Development
Table 96. Genfit Company Details
Table 97. Genfit Business Overview
Table 98. Genfit Product
Table 99. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 100. Genfit Recent Development
Table 101. Gilead Company Details
Table 102. Gilead Business Overview
Table 103. Gilead Product
Table 104. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 105. Gilead Recent Development
Table 106. Horizon Pharma Company Details
Table 107. Horizon Pharma Business Overview
Table 108. Horizon Pharma Product
Table 109. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 110. Horizon Pharma Recent Development
Table 111. Immuron Business Overview
Table 112. Immuron Product
Table 113. Immuron Company Details
Table 114. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 115. Immuron Recent Development
Table 116. Intercept Pharmaceuticals Company Details
Table 117. Intercept Pharmaceuticals Business Overview
Table 118. Intercept Pharmaceuticals Product
Table 119. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 120. Intercept Pharmaceuticals Recent Development
Table 121. Novo Nordisk Company Details
Table 122. Novo Nordisk Business Overview
Table 123. Novo Nordisk Product
Table 124. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (Million US$)
Table 125. Novo Nordisk Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Vitamin E & Pioglitazone Features
Figure 3. Obeticholic Acid (OCA) Features
Figure 4. Elafibranor Features
Figure 5. Selonsertib & Cenicriviroc Features
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2019
Figure 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed


【掲載企業】

AstraZeneca、Conatus Pharmaceuticals、Enzo Biochem、Galmed Pharmaceuticals、Genfit、Gilead、Horizon Pharma、Immuron、Intercept Pharmaceuticals、Novo Nordisk

★調査レポート[世界の非アルコール性脂肪性肝炎(NASH)治療薬市場インサイト及び予測(~2026年)] (コード:QYR20NV03995)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の非アルコール性脂肪性肝炎(NASH)治療薬市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆